Compare OXSQ & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXSQ | PROF |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.4M | 199.3M |
| IPO Year | N/A | N/A |
| Metric | OXSQ | PROF |
|---|---|---|
| Price | $1.85 | $7.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | ★ 641.5K | 98.5K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | ★ 22.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,142,565.00 | $14,297,000.00 |
| Revenue This Year | N/A | $64.23 |
| Revenue Next Year | $2.27 | $113.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 67.94 |
| 52 Week Low | $1.56 | $3.76 |
| 52 Week High | $2.87 | $7.99 |
| Indicator | OXSQ | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 50.19 | 64.32 |
| Support Level | $1.82 | $6.09 |
| Resistance Level | $1.87 | $7.53 |
| Average True Range (ATR) | 0.03 | 0.41 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 75.00 | 86.11 |
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.